Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causin... Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients. Mostrar más
KT-621 (STAT6) Phase 1 healthy volunteer trial ongoing, with data expected in 2Q25 Kymera plans to initiate a KT-621 Phase 1b trial in atopic dermatitis (AD) patients in 2Q25 with data in 4Q25...
WATERTOWN, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader...
WATERTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using...
WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using...
| Período † | Variación(Ptos) | Variación % | Apertura | Precio Máximo | Precio Mínimo | Avg. Vol. diario | Precio Promedio Ponderado | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.43 | 1.03614457831 | 41.5 | 45.31 | 41.5 | 546620 | 44.1412984 | CS |
| 4 | 2.24 | 5.64373897707 | 39.69 | 45.31 | 35.57 | 538078 | 41.02420072 | CS |
| 12 | -4.17 | -9.04555314534 | 46.1 | 53.23 | 35.57 | 483328 | 43.3586448 | CS |
| 26 | -2.75 | -6.15487914056 | 44.68 | 53.27 | 35.57 | 446629 | 44.93954749 | CS |
| 52 | 10.9 | 35.127296165 | 31.03 | 53.27 | 29.24 | 535870 | 40.45301294 | CS |
| 156 | 1.97 | 4.92992992993 | 39.96 | 53.27 | 9.6 | 605937 | 29.89494721 | CS |
| 260 | 9.01 | 27.3693803159 | 32.92 | 91.92 | 9.6 | 512415 | 34.28378469 | CS |
Parece que no se ha autenticado. Haga click al botón de abajo para iniciar la sesión y ver los símbolos recientemente consultados.
Soporte: (55) 4170 8128 | soporte@advfn.mx
Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones
Hot Features
Premium
